Product Information
LGD 3303 is a selective estrogen receptor modulator that has been shown to have therapeutic potential for the treatment of metabolic disorders and cancer. LGD 3303 binds to the estrogen receptor alpha (ERα) and beta (ERβ), which has been shown to inhibit the proliferation of human breast cancer cells in vitro. It also inhibits adipose tissue growth, increases bone growth, and improves blood pressure regulation. LGD 3303 has been shown to have beneficial effects on metabolic disorders such as insulin resistance, obesity, and diabetes. This drug may also be able to treat inflammatory diseases such as arthritis or skin conditions like atopic dermatitis in animals.
Chemical properties
Technical inquiry about: 3D-FL102146 LGD 3303
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
